Bimiralisib suppresses proliferation and migration of gastric cancer cells via PI3K/mTOR pathway inhibition
The Korean Journal of Physiology & Pharmacology · 08.07.2026
DOI: 10.4196/kjpp.26.137 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Korean Journal of Physiology & Pharmacology, online erschienen am 08.07.2026. Verfasst von You Jin Noh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, College of Medicine, Dankook University, Cheonan 31116, Korea. Gefördert von: Dankook University.
Abstract (Originalsprache)
Gastric cancer remains a leading cause of cancer-related mortality worldwide, underscoring the need for effective targeted therapeutic strategies. The phosphatidylinositol 3-kinase (PI3K)/mechanistic target of rapamycin (mTOR) signaling pathway is frequently dysregulated in gastric cancer and represents a promising therapeutic target. However, its clinical applicability remains insufficiently explored. Therefore, this study aimed to identify actionable therapeutic targets and evaluate the potential of a clinically relevant PI3K/mTOR inhibitor, bimiralisib, in gastric cancer. Analysis of The Cancer Genome Atlas dataset revealed elevated expression of PIK3CA and mTOR in gastric cancer tissues. Small-molecule inhibitor screening identified bimiralisib as a potent suppressor of gastric cancer cell viability. Functional assays demonstrated that bimiralisib significantly inhibited cell proliferation, clonogenic growth, spheroid formation, and migration, and induced G1 phase arrest with a reduction in the S phase population. Mechanistically, bimiralisib reduced phosphorylation of AKT and mTOR, confirming effective inhibition of PI3K/mTOR signaling. Consistently, PIK3CA knockdown recapitulated these effects. In addition, bimiralisib treatment was associated with upregulation of E2F4, suggesting a link between pathway inhibition and cell cycle regulation. Collectively, these findings demonstrate that targeting PI3K/mTOR signaling with bimiralisib suppresses gastric cancer cell growth and migration, supporting its potential as a targeted therapeutic strategy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Microbiology, College of Medicine, Dankook University, Cheonan 31116, Korea.
- Cancer Research Center for Precision Medicine (CRCPM), Dankook University, Cheonan 31116, Korea.
- Medical Research Center, Chest Hospital of Zhengzhou University, Zhengzhou 450008, China.
ORCID-Profile: Xiaomeng Xie, Dong Joon Kim
Förderung
- Dankook University
Zitieren
APA
Noh, Y. J., Jeong, H. E., Cha, S. H., Shin, Y. R., Xie, X., & Kim, D. J. (2026). Bimiralisib suppresses proliferation and migration of gastric cancer cells via PI3K/mTOR pathway inhibition. The Korean Journal of Physiology & Pharmacology. https://doi.org/10.4196/kjpp.26.137
Vancouver
Noh YJ, Jeong HE, Cha SH, Shin YR, Xie X, Kim DJ. Bimiralisib suppresses proliferation and migration of gastric cancer cells via PI3K/mTOR pathway inhibition. The Korean Journal of Physiology & Pharmacology. 2026. doi:10.4196/kjpp.26.137
BibTeX
@article{Noh2026,
author = {Noh, You Jin and Jeong, Hye Eun and Cha, Seo Hyun and Shin, Young Ran and Xie, Xiaomeng and Kim, Dong Joon},
title = {Bimiralisib suppresses proliferation and migration of gastric cancer cells via PI3K/mTOR pathway inhibition},
journal = {The Korean Journal of Physiology & Pharmacology},
year = {2026},
doi = {10.4196/kjpp.26.137}
}
EUVIMED